Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A 24 (CDCA1,KIF20A) in Patients With Small Cell Lung Cancer Refractory to Standard Therapy.

Next Previous
Search
Trial Profile

Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A 24 (CDCA1,KIF20A) in Patients With Small Cell Lung Cancer Refractory to Standard Therapy.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDCA1 peptide vaccine (Primary) ; KIF20A peptide vaccine (Primary) ; Montanide ISA-51
  • Indications Small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Mar 2019 Biomarkers information updated
    • 17 Sep 2013 Planned end date changed from 31 Oct 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 06 Dec 2012 Planned end date changed from 1 Oct 2013 to 31 Oct 2013 as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top